These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 17644552

  • 1. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
    Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J.
    Ann Rheum Dis; 2008 Apr; 67(4):511-7. PubMed ID: 17644552
    [Abstract] [Full Text] [Related]

  • 2. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
    Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, Van Der Heijde D.
    Arthritis Rheum; 2003 Apr; 48(4):1126-36. PubMed ID: 12687557
    [Abstract] [Full Text] [Related]

  • 3. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.
    Arthritis Rheum; 2009 Nov 15; 61(11):1484-90. PubMed ID: 19877087
    [Abstract] [Full Text] [Related]

  • 4. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab.
    Braun J, van der Heijde D, Doyle MK, Han C, Deodhar A, Inman R, de Vlam K, Burmester GR, Van den Bosch F, Xu S, Visvanathan S, Rahman MU.
    Arthritis Rheum; 2009 Aug 15; 61(8):1032-6. PubMed ID: 19644896
    [Abstract] [Full Text] [Related]

  • 5. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
    Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Braun J.
    Rheumatology (Oxford); 2005 Dec 15; 44(12):1525-30. PubMed ID: 16091396
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
    Arthritis Rheum; 2005 Feb 15; 52(2):582-91. PubMed ID: 15692973
    [Abstract] [Full Text] [Related]

  • 7. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J.
    Arthritis Rheum; 2000 Jun 15; 43(6):1346-52. PubMed ID: 10857793
    [Abstract] [Full Text] [Related]

  • 8. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 19; 86(35):2451-4. PubMed ID: 17156669
    [Abstract] [Full Text] [Related]

  • 9. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
    Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J.
    Ann Rheum Dis; 2008 Sep 19; 67(9):1276-81. PubMed ID: 18006539
    [Abstract] [Full Text] [Related]

  • 10. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Rheumatology (Oxford); 2005 May 19; 44(5):670-6. PubMed ID: 15757965
    [Abstract] [Full Text] [Related]

  • 11. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
    Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'connor P, Tan AL, Conaghan PG, Greenstein A, Emery P.
    Ann Rheum Dis; 2005 Nov 19; 64(11):1568-75. PubMed ID: 15829577
    [Abstract] [Full Text] [Related]

  • 12. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC.
    J Rheumatol; 2005 Oct 19; 32(10):1911-7. PubMed ID: 16206346
    [Abstract] [Full Text] [Related]

  • 13. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.
    Ann Rheum Dis; 2004 Jun 19; 63(6):665-70. PubMed ID: 15037444
    [Abstract] [Full Text] [Related]

  • 14. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study.
    Braun J, Landewé R, Hermann KG, Han J, Yan S, Williamson P, van der Heijde D, ASSERT Study Group.
    Arthritis Rheum; 2006 May 19; 54(5):1646-52. PubMed ID: 16646033
    [Abstract] [Full Text] [Related]

  • 15. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.
    van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, Bala M, Han J, Braun J.
    Arthritis Rheum; 2006 Aug 15; 55(4):569-74. PubMed ID: 16874778
    [Abstract] [Full Text] [Related]

  • 16. Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study.
    Maksymowych WP, Salonen D, Inman RD, Rahman P, Lambert RG, CANDLE Study Group.
    J Rheumatol; 2010 Aug 01; 37(8):1728-34. PubMed ID: 20436073
    [Abstract] [Full Text] [Related]

  • 17. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response.
    Kim TH, Stone M, Payne U, Zhang X, Ionescu M, Lobanok T, King L, Poole AR, Inman RD.
    Arthritis Rheum; 2005 Mar 01; 52(3):885-91. PubMed ID: 15751093
    [Abstract] [Full Text] [Related]

  • 18. Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
    Cheung PP, Tymms KE, Wilson BJ, Shadbolt B, Brook AS, Dorai Raj AK, Khoo KB.
    Intern Med J; 2008 Jun 01; 38(6):396-401. PubMed ID: 18336538
    [Abstract] [Full Text] [Related]

  • 19. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2005 Dec 15; 53(6):856-63. PubMed ID: 16342093
    [Abstract] [Full Text] [Related]

  • 20. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH, Lee HJ, Sung IH, Kim TH.
    J Rheumatol; 2007 Aug 15; 34(8):1753-9. PubMed ID: 17610317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.